Krónikus szívelégtelenség - A 21. Század epidémiája

Translated title of the contribution: Chronic heart failure - An epidemic of the 21 st century

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Heart failure represents a major public health problem in the industrialized countries and despite of optimal medical treatment its mortality remains high. The history of its management reflects growth and changes in our understanding of its pathophysiology. In the past, pharmacological treatment of heart failure was aimed only at relieving edema and improving hemodynamics. Today, however, a major aim of treatment is to antagonize the sympathetic nervous system and renin-angiotensin-aldosteron system, to avert harmful effects of neurohormonal activation on the myocardium and periferal vessels. Currently, the major pharmacological treatments for heart failure are diuretics, ACE inhibitors, beta-blockers and (in NYHA classes III-IV) aldosterone antagonists. Some patients may also require specific treatment with additional drugs (e.g. antiarrhytthmic agents, anticoagulants, or vasodilators) or procedures such as coronary revascularization, or implantable devices such as pacemakers and implantable cardioverter defibrillators, or resynchronization devices. Patients with end-stage heart failure may require cardiac transplantation or ventricular assist devices. This review is summarized the recent practical drug therapy of heart failure and the results of the newer clinical trial.

Original languageHungarian
Pages (from-to)1075-1087
Number of pages13
JournalOrvosi Hetilap
Volume146
Issue number20 SUPPL. 2
Publication statusPublished - 2005

Fingerprint

Heart Failure
Treatment Failure
Pharmacology
Mineralocorticoid Receptor Antagonists
Equipment and Supplies
Heart-Assist Devices
Implantable Defibrillators
Sympathetic Nervous System
Heart Transplantation
Renin-Angiotensin System
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Developed Countries
Anticoagulants
Edema
Myocardium
Therapeutics
Public Health
Hemodynamics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Krónikus szívelégtelenség - A 21. Század epidémiája. / Czuriga, I.

In: Orvosi Hetilap, Vol. 146, No. 20 SUPPL. 2, 2005, p. 1075-1087.

Research output: Contribution to journalArticle

Czuriga, I. / Krónikus szívelégtelenség - A 21. Század epidémiája. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 20 SUPPL. 2. pp. 1075-1087.
@article{aa915b5b64c249c9aa341fbc3377a5cb,
title = "Kr{\'o}nikus sz{\'i}vel{\'e}gtelens{\'e}g - A 21. Sz{\'a}zad epid{\'e}mi{\'a}ja",
abstract = "Heart failure represents a major public health problem in the industrialized countries and despite of optimal medical treatment its mortality remains high. The history of its management reflects growth and changes in our understanding of its pathophysiology. In the past, pharmacological treatment of heart failure was aimed only at relieving edema and improving hemodynamics. Today, however, a major aim of treatment is to antagonize the sympathetic nervous system and renin-angiotensin-aldosteron system, to avert harmful effects of neurohormonal activation on the myocardium and periferal vessels. Currently, the major pharmacological treatments for heart failure are diuretics, ACE inhibitors, beta-blockers and (in NYHA classes III-IV) aldosterone antagonists. Some patients may also require specific treatment with additional drugs (e.g. antiarrhytthmic agents, anticoagulants, or vasodilators) or procedures such as coronary revascularization, or implantable devices such as pacemakers and implantable cardioverter defibrillators, or resynchronization devices. Patients with end-stage heart failure may require cardiac transplantation or ventricular assist devices. This review is summarized the recent practical drug therapy of heart failure and the results of the newer clinical trial.",
keywords = "Clinical trials, Heart failure, Medical therapy, Novel therapies",
author = "I. Czuriga",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "1075--1087",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "20 SUPPL. 2",

}

TY - JOUR

T1 - Krónikus szívelégtelenség - A 21. Század epidémiája

AU - Czuriga, I.

PY - 2005

Y1 - 2005

N2 - Heart failure represents a major public health problem in the industrialized countries and despite of optimal medical treatment its mortality remains high. The history of its management reflects growth and changes in our understanding of its pathophysiology. In the past, pharmacological treatment of heart failure was aimed only at relieving edema and improving hemodynamics. Today, however, a major aim of treatment is to antagonize the sympathetic nervous system and renin-angiotensin-aldosteron system, to avert harmful effects of neurohormonal activation on the myocardium and periferal vessels. Currently, the major pharmacological treatments for heart failure are diuretics, ACE inhibitors, beta-blockers and (in NYHA classes III-IV) aldosterone antagonists. Some patients may also require specific treatment with additional drugs (e.g. antiarrhytthmic agents, anticoagulants, or vasodilators) or procedures such as coronary revascularization, or implantable devices such as pacemakers and implantable cardioverter defibrillators, or resynchronization devices. Patients with end-stage heart failure may require cardiac transplantation or ventricular assist devices. This review is summarized the recent practical drug therapy of heart failure and the results of the newer clinical trial.

AB - Heart failure represents a major public health problem in the industrialized countries and despite of optimal medical treatment its mortality remains high. The history of its management reflects growth and changes in our understanding of its pathophysiology. In the past, pharmacological treatment of heart failure was aimed only at relieving edema and improving hemodynamics. Today, however, a major aim of treatment is to antagonize the sympathetic nervous system and renin-angiotensin-aldosteron system, to avert harmful effects of neurohormonal activation on the myocardium and periferal vessels. Currently, the major pharmacological treatments for heart failure are diuretics, ACE inhibitors, beta-blockers and (in NYHA classes III-IV) aldosterone antagonists. Some patients may also require specific treatment with additional drugs (e.g. antiarrhytthmic agents, anticoagulants, or vasodilators) or procedures such as coronary revascularization, or implantable devices such as pacemakers and implantable cardioverter defibrillators, or resynchronization devices. Patients with end-stage heart failure may require cardiac transplantation or ventricular assist devices. This review is summarized the recent practical drug therapy of heart failure and the results of the newer clinical trial.

KW - Clinical trials

KW - Heart failure

KW - Medical therapy

KW - Novel therapies

UR - http://www.scopus.com/inward/record.url?scp=22144461427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144461427&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 1075

EP - 1087

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 20 SUPPL. 2

ER -